Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ANAB

Stock Name	AnaptysBio Inc
Ticker	ANAB(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0327241065
LEI	529900HH4WQT03IG1A12

Show aggregate ANAB holdings

News associated with ANAB

AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $45.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 127.16% from the company’s current price. Several other […] - 2025-09-18 02:24:44
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.13: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy […] - 2025-09-16 02:46:48
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.13 Average Target Price from Analysts: Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to […] - 2025-08-22 03:12:54
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group: UBS Group restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock, up from their prior price target of $18.00. A number of other research analysts have also […] - 2025-08-13 04:26:45
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB): Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 24.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,062 shares of the biotechnology company’s stock after selling 660 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-11 05:32:56
Federated Hermes Inc. Has $154,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Federated Hermes Inc. lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,274 shares of the biotechnology company’s stock after selling 36,910 shares during the quarter. Federated Hermes Inc.’s holdings […] - 2025-08-11 04:48:58
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The […] - 2025-07-30 04:24:54
Alps Advisors Inc. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB): Alps Advisors Inc. trimmed its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,126 shares of the biotechnology company’s stock after selling 1,478 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:26:00
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $42.38: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-07-03 02:41:00
AnaptysBio (NASDAQ:ANAB) Upgraded at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock, up from their previous price objective of $22.00. HC Wainwright’s […] - 2025-06-06 02:58:51
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Squarepoint Ops LLC: Squarepoint Ops LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,870 shares of the biotechnology company’s stock after purchasing an additional 36,365 shares during the period. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $1,071,000 as of its most recent filing […] - 2025-06-01 05:29:02
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $90.00 target price on the biotechnology company’s stock, up from their previous target price of $54.00. Guggenheim’s price objective points to a […] - 2025-05-30 03:08:51
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $52.00 to $54.00. The stock had previously closed at $20.13, but opened at $21.14. Guggenheim currently has a buy rating on the stock. AnaptysBio shares last traded at $22.10, […] - 2025-05-30 02:27:21
D. E. Shaw & Co. Inc. Reduces Stake in AnaptysBio, Inc. (NASDAQ:ANAB): D. E. Shaw & Co. Inc. trimmed its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 197,107 shares of the biotechnology company’s stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc.’s holdings in AnaptysBio were worth $2,610,000 as […] - 2025-05-20 04:57:05
18,954 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Bought by Graham Capital Management L.P.: Graham Capital Management L.P. bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 18,954 shares of the biotechnology company’s stock, valued at approximately $251,000. Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased […] - 2025-05-19 05:26:52
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.88: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-05-14 02:34:53
Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB): Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 05:26:54
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.: Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 05:18:48
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.: Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 04:22:49
Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO): AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 03:56:46
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 03:52:42
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.: AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 04:10:52
AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright: AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 06:31:49
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20: AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 04:26:55
Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB): Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 07:55:30
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB): AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 04:36:55
Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB): Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 07:10:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ANAB holdings

Date	Number of ANAB Shares Held	Base Market Value of ANAB Shares	Local Market Value of ANAB Shares	Change in ANAB Shares Held	Change in ANAB Base Value	Current Price per ANAB Share Held	Previous Price per ANAB Share Held
2025-12-11 (Thursday)	3,122	USD 142,925	USD 142,925	0	USD 2,591	USD 45.7799	USD 44.95
2025-12-10 (Wednesday)	3,122	USD 140,334	USD 140,334	0	USD 3,590	USD 44.95	USD 43.8001
2025-12-09 (Tuesday)	3,122	USD 136,744	USD 136,744	0	USD -2,216	USD 43.8001	USD 44.5099
2025-12-08 (Monday)	3,122	USD 138,960	USD 138,960	0	USD 499	USD 44.5099	USD 44.3501
2025-12-05 (Friday)	3,122	USD 138,461	USD 138,461	0	USD 3,278	USD 44.3501	USD 43.3001
2025-12-04 (Thursday)	3,122	USD 135,183	USD 135,183	0	USD -1,436	USD 43.3001	USD 43.7601
2025-12-03 (Wednesday)	3,122	USD 136,619	USD 136,619	-55	USD 6,680	USD 43.7601	USD 40.8999
2025-12-02 (Tuesday)	3,177	USD 129,939	USD 129,939	22	USD -394	USD 40.8999	USD 41.31
2025-12-01 (Monday)	3,155	USD 130,333	USD 130,333	0	USD -1,073	USD 41.31	USD 41.6501
2025-11-28 (Friday)	3,155	USD 131,406	USD 131,406	0	USD -1,609	USD 41.6501	USD 42.1601
2025-11-27 (Thursday)	3,155	USD 133,015	USD 133,015	0	USD 0	USD 42.1601	USD 42.1601
2025-11-26 (Wednesday)	3,155	USD 133,015	USD 133,015	0	USD 2,082	USD 42.1601	USD 41.5002

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ANAB by Blackrock for IE00B3VWM098

Show aggregate share trades of ANAB

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 SELL -55 44.285 40.630 40.996 USD -2,255 23.85 Loss of -943 on sale
2025-12-02 BUY 22 41.870 40.545 40.677 USD 895 23.77
2025-11-25 SELL -33 42.274 39.940 40.173 USD -1,326 23.33 Loss of -556 on sale
2025-11-24 SELL -2,658 43.310 39.020 39.449 USD -104,855 23.24 Loss of -43,073 on sale
2025-11-17 SELL -209 35.140 33.010 33.223 USD -6,944 22.89 Loss of -2,159 on sale
2025-11-12 SELL -19 34.300 32.925 33.062 USD -628 22.74 Loss of -196 on sale
2025-11-06 SELL -19 40.960 35.910 36.415 USD -692 22.45 Loss of -265 on sale
2025-11-05 SELL -190 39.780 34.220 34.776 USD -6,607 22.38 Loss of -2,355 on sale
2025-11-04 SELL -38 36.500 34.595 34.786 USD -1,322 22.32 Loss of -474 on sale
2025-11-03 SELL -38 37.120 35.535 35.693 USD -1,356 22.25 Loss of -511 on sale
2025-10-28 BUY 57 36.160 37.000 36.916 USD 2,104 21.94
2025-10-24 SELL -19 35.070 35.145 35.138 USD -668 21.79 Loss of -254 on sale
2025-10-15 BUY 114 34.290 34.415 34.403 USD 3,922 21.30
2025-10-02 BUY 19 31.340 32.150 32.069 USD 609 21.19
2025-10-01 BUY 38 31.970 33.480 33.329 USD 1,267 21.12
2025-09-11 BUY 76 23.200 23.635 23.592 USD 1,793 21.03
2025-08-21 SELL -3 20.360 20.570 20.549 USD -62 21.03 Profit of 1 on sale
2025-07-31 BUY 9 24.550 25.255 25.184 USD 227 21.02
2025-06-30 SELL -6 22.200 22.830 22.767 USD -137 20.47 Loss of -14 on sale
2025-06-25 SELL -3 23.240 23.590 23.555 USD -71 20.42 Loss of -9 on sale
2025-06-20 SELL -6 23.170 23.450 23.422 USD -141 20.36 Loss of -18 on sale
2025-05-30 SELL -4,505 22.230 22.590 22.554 USD -101,606 20.03 Loss of -11,349 on sale
2025-05-23 BUY 18 20.440 20.750 20.719 USD 373 20.00
2025-05-19 SELL -18 20.470 20.730 20.704 USD -373 19.97 Loss of -13 on sale
2025-05-15 SELL -54 20.400 20.790 20.751 USD -1,121 19.97 Loss of -42 on sale
2025-05-12 SELL -18 20.030 21.140 21.029 USD -379 19.97 Loss of -19 on sale
2025-05-09 SELL -18 19.590 20.040 19.995 USD -360 19.97 Loss of 0 on sale
2025-04-30 SELL -18 22.220 22.515 22.485 USD -405 19.92 Loss of -46 on sale
2025-04-24 SELL -36 20.610 20.680 20.673 USD -744 19.87 Loss of -29 on sale
2025-04-17 SELL -18 20.550 20.750 20.730 USD -373 19.83 Loss of -16 on sale
2025-04-15 SELL -54 18.100 18.650 18.595 USD -1,004 19.85 Profit of 68 on sale
2025-04-14 SELL -54 17.860 18.090 18.067 USD -976 19.88 Profit of 98 on sale
2025-04-09 SELL -72 16.900 18.130 18.007 USD -1,297 19.98 Profit of 142 on sale
2025-04-07 SELL -126 17.780 18.740 18.644 USD -2,349 20.04 Profit of 176 on sale
2025-04-04 SELL -180 18.510 19.360 19.275 USD -3,470 20.06 Profit of 141 on sale
2025-03-31 BUY 18 18.590 18.805 18.784 USD 338 20.11
2025-03-19 SELL -36 16.440 16.540 16.530 USD -595 20.34 Profit of 137 on sale
2025-03-14 SELL -108 16.730 17.730 17.630 USD -1,904 20.50 Profit of 310 on sale
2025-03-13 SELL -36 16.840 18.080 17.956 USD -646 20.56 Profit of 94 on sale
2025-03-12 SELL -612 17.710 18.500 18.421 USD -11,274 20.60 Profit of 1,332 on sale
2025-03-07 SELL -36 16.340 17.205 17.118 USD -616 20.77 Profit of 131 on sale
2025-03-06 SELL -54 16.400 16.790 16.751 USD -905 20.83 Profit of 221 on sale
2025-03-03 SELL -18 14.640 17.260 16.998 USD -306 21.09 Profit of 74 on sale
2025-02-28 SELL -29,302 16.820 19.450 19.187 USD -562,217 21.16 Profit of 57,830 on sale
2025-02-26 SELL -95 17.000 17.760 17.684 USD -1,680 21.31 Profit of 345 on sale
2025-02-25 SELL -288 17.190 17.600 17.559 USD -5,057 21.38 Profit of 1,101 on sale
2025-02-18 BUY 475 19.780 21.570 21.391 USD 10,161 21.63
2025-02-13 BUY 190 19.290 19.360 19.353 USD 3,677 21.69
2025-02-11 BUY 285 12.375 12.990 12.928 USD 3,685 22.00
2025-02-06 BUY 855 16.080 16.180 16.170 USD 13,825 22.49
2025-01-27 BUY 95 17.460 17.730 17.703 USD 1,682 23.64
2024-12-30 BUY 475 13.220 13.340 13.328 USD 6,331 24.69
2024-12-06 BUY 380 24.810 24.950 24.936 USD 9,476 24.80
2024-12-05 BUY 95 23.660 25.470 25.289 USD 2,402 24.84
2024-12-04 BUY 475 24.080 24.700 24.638 USD 11,703 24.86
2024-11-29 BUY 475 24.960 25.680 25.608 USD 12,164 24.99
2024-11-27 BUY 380 25.120 26.510 26.371 USD 10,021 24.98
2024-11-26 BUY 95 25.250 25.320 25.313 USD 2,405 24.97
2024-11-25 BUY 9,821 24.100 25.110 25.009 USD 245,613 25.01
2024-11-21 BUY 325 21.170 21.640 21.593 USD 7,018 25.36
2024-11-20 BUY 195 20.310 20.590 20.562 USD 4,010 25.64
2024-11-18 BUY 780 18.880 19.240 19.204 USD 14,979 26.41
2024-11-12 BUY 520 21.500 22.805 22.675 USD 11,791 26.74
2024-11-08 BUY 325 21.310 21.805 21.756 USD 7,071 27.13
2024-11-07 BUY 975 21.490 22.620 22.507 USD 21,944 27.56
2024-11-06 BUY 130 22.210 22.950 22.876 USD 2,974 28.01
2024-10-31 BUY 65 21.630 22.475 22.391 USD 1,455 31.62
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	SELL	-55	44.285	40.630	40.996	USD -2,255	23.85 Loss of -943 on sale
2025-12-02	BUY	22	41.870	40.545	40.677	USD 895	23.77
2025-11-25	SELL	-33	42.274	39.940	40.173	USD -1,326	23.33 Loss of -556 on sale
2025-11-24	SELL	-2,658	43.310	39.020	39.449	USD -104,855	23.24 Loss of -43,073 on sale
2025-11-17	SELL	-209	35.140	33.010	33.223	USD -6,944	22.89 Loss of -2,159 on sale
2025-11-12	SELL	-19	34.300	32.925	33.062	USD -628	22.74 Loss of -196 on sale
2025-11-06	SELL	-19	40.960	35.910	36.415	USD -692	22.45 Loss of -265 on sale
2025-11-05	SELL	-190	39.780	34.220	34.776	USD -6,607	22.38 Loss of -2,355 on sale
2025-11-04	SELL	-38	36.500	34.595	34.786	USD -1,322	22.32 Loss of -474 on sale
2025-11-03	SELL	-38	37.120	35.535	35.693	USD -1,356	22.25 Loss of -511 on sale
2025-10-28	BUY	57	36.160	37.000	36.916	USD 2,104	21.94
2025-10-24	SELL	-19	35.070	35.145	35.138	USD -668	21.79 Loss of -254 on sale
2025-10-15	BUY	114	34.290	34.415	34.403	USD 3,922	21.30
2025-10-02	BUY	19	31.340	32.150	32.069	USD 609	21.19
2025-10-01	BUY	38	31.970	33.480	33.329	USD 1,267	21.12
2025-09-11	BUY	76	23.200	23.635	23.592	USD 1,793	21.03
2025-08-21	SELL	-3	20.360	20.570	20.549	USD -62	21.03 Profit of 1 on sale
2025-07-31	BUY	9	24.550	25.255	25.184	USD 227	21.02
2025-06-30	SELL	-6	22.200	22.830	22.767	USD -137	20.47 Loss of -14 on sale
2025-06-25	SELL	-3	23.240	23.590	23.555	USD -71	20.42 Loss of -9 on sale
2025-06-20	SELL	-6	23.170	23.450	23.422	USD -141	20.36 Loss of -18 on sale
2025-05-30	SELL	-4,505	22.230	22.590	22.554	USD -101,606	20.03 Loss of -11,349 on sale
2025-05-23	BUY	18	20.440	20.750	20.719	USD 373	20.00
2025-05-19	SELL	-18	20.470	20.730	20.704	USD -373	19.97 Loss of -13 on sale
2025-05-15	SELL	-54	20.400	20.790	20.751	USD -1,121	19.97 Loss of -42 on sale
2025-05-12	SELL	-18	20.030	21.140	21.029	USD -379	19.97 Loss of -19 on sale
2025-05-09	SELL	-18	19.590	20.040	19.995	USD -360	19.97 Loss of 0 on sale
2025-04-30	SELL	-18	22.220	22.515	22.485	USD -405	19.92 Loss of -46 on sale
2025-04-24	SELL	-36	20.610	20.680	20.673	USD -744	19.87 Loss of -29 on sale
2025-04-17	SELL	-18	20.550	20.750	20.730	USD -373	19.83 Loss of -16 on sale
2025-04-15	SELL	-54	18.100	18.650	18.595	USD -1,004	19.85 Profit of 68 on sale
2025-04-14	SELL	-54	17.860	18.090	18.067	USD -976	19.88 Profit of 98 on sale
2025-04-09	SELL	-72	16.900	18.130	18.007	USD -1,297	19.98 Profit of 142 on sale
2025-04-07	SELL	-126	17.780	18.740	18.644	USD -2,349	20.04 Profit of 176 on sale
2025-04-04	SELL	-180	18.510	19.360	19.275	USD -3,470	20.06 Profit of 141 on sale
2025-03-31	BUY	18	18.590	18.805	18.784	USD 338	20.11
2025-03-19	SELL	-36	16.440	16.540	16.530	USD -595	20.34 Profit of 137 on sale
2025-03-14	SELL	-108	16.730	17.730	17.630	USD -1,904	20.50 Profit of 310 on sale
2025-03-13	SELL	-36	16.840	18.080	17.956	USD -646	20.56 Profit of 94 on sale
2025-03-12	SELL	-612	17.710	18.500	18.421	USD -11,274	20.60 Profit of 1,332 on sale
2025-03-07	SELL	-36	16.340	17.205	17.118	USD -616	20.77 Profit of 131 on sale
2025-03-06	SELL	-54	16.400	16.790	16.751	USD -905	20.83 Profit of 221 on sale
2025-03-03	SELL	-18	14.640	17.260	16.998	USD -306	21.09 Profit of 74 on sale
2025-02-28	SELL	-29,302	16.820	19.450	19.187	USD -562,217	21.16 Profit of 57,830 on sale
2025-02-26	SELL	-95	17.000	17.760	17.684	USD -1,680	21.31 Profit of 345 on sale
2025-02-25	SELL	-288	17.190	17.600	17.559	USD -5,057	21.38 Profit of 1,101 on sale
2025-02-18	BUY	475	19.780	21.570	21.391	USD 10,161	21.63
2025-02-13	BUY	190	19.290	19.360	19.353	USD 3,677	21.69
2025-02-11	BUY	285	12.375	12.990	12.928	USD 3,685	22.00
2025-02-06	BUY	855	16.080	16.180	16.170	USD 13,825	22.49
2025-01-27	BUY	95	17.460	17.730	17.703	USD 1,682	23.64
2024-12-30	BUY	475	13.220	13.340	13.328	USD 6,331	24.69
2024-12-06	BUY	380	24.810	24.950	24.936	USD 9,476	24.80
2024-12-05	BUY	95	23.660	25.470	25.289	USD 2,402	24.84
2024-12-04	BUY	475	24.080	24.700	24.638	USD 11,703	24.86
2024-11-29	BUY	475	24.960	25.680	25.608	USD 12,164	24.99
2024-11-27	BUY	380	25.120	26.510	26.371	USD 10,021	24.98
2024-11-26	BUY	95	25.250	25.320	25.313	USD 2,405	24.97
2024-11-25	BUY	9,821	24.100	25.110	25.009	USD 245,613	25.01
2024-11-21	BUY	325	21.170	21.640	21.593	USD 7,018	25.36
2024-11-20	BUY	195	20.310	20.590	20.562	USD 4,010	25.64
2024-11-18	BUY	780	18.880	19.240	19.204	USD 14,979	26.41
2024-11-12	BUY	520	21.500	22.805	22.675	USD 11,791	26.74
2024-11-08	BUY	325	21.310	21.805	21.756	USD 7,071	27.13
2024-11-07	BUY	975	21.490	22.620	22.507	USD 21,944	27.56
2024-11-06	BUY	130	22.210	22.950	22.876	USD 2,974	28.01
2024-10-31	BUY	65	21.630	22.475	22.391	USD 1,455	31.62

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANAB

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	92,308	0	183,005	50.4%
2025-09-18	58,201	0	106,687	54.6%
2025-09-17	105,431	873	320,514	32.9%
2025-09-16	191,351	14,369	566,480	33.8%
2025-09-15	166,542	12,680	469,729	35.5%
2025-09-12	122,619	0	188,382	65.1%
2025-09-11	107,589	0	138,671	77.6%
2025-09-10	122,385	0	174,863	70.0%
2025-09-09	69,966	0	98,957	70.7%
2025-09-08	74,734	0	107,417	69.6%
2025-09-05	75,329	0	104,698	71.9%
2025-09-04	113,219	0	168,716	67.1%
2025-09-03	102,133	0	140,378	72.8%
2025-09-02	29,714	122	45,208	65.7%
2025-08-29	105,678	0	137,685	76.8%
2025-08-28	18,607	0	46,589	39.9%
2025-08-27	47,648	870	76,479	62.3%
2025-08-26	48,080	1,000	99,553	48.3%
2025-08-25	35,311	0	52,989	66.6%
2025-08-22	54,262	328	78,722	68.9%
2025-08-21	83,095	2,019	146,968	56.5%
2025-08-20	58,202	0	101,839	57.2%
2025-08-19	69,349	0	109,095	63.6%
2025-08-18	45,757	300	66,872	68.4%
2025-08-15	49,379	0	85,030	58.1%
2025-08-14	51,063	1	93,195	54.8%
2025-08-13	176,608	66	417,787	42.3%
2025-08-12	48,149	0	98,556	48.9%
2025-08-11	70,002	0	155,360	45.1%
2025-08-08	139,058	21,803	613,210	22.7%
2025-08-07	79,784	643	173,811	45.9%
2025-08-06	77,521	3	179,677	43.1%
2025-08-05	65,167	0	161,070	40.5%
2025-08-04	27,989	0	67,303	41.6%
2025-08-01	45,155	0	116,703	38.7%
2025-07-31	84,525	960	201,920	41.9%
2025-07-30	155,697	816	333,900	46.6%
2025-07-29	57,495	60	119,685	48.0%
2025-07-28	59,023	0	119,581	49.4%
2025-07-25	73,692	49	186,893	39.4%
2025-07-24	70,238	54	146,166	48.1%
2025-07-23	92,577	1,556	353,307	26.2%
2025-07-22	55,841	4,032	156,457	35.7%
2025-07-21	102,030	40	188,906	54.0%
2025-07-18	50,078	9	80,374	62.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE